CardioExchange Archive

January 30th, 2013

How Insurance Status Affects Treatment for Patients with CAD

Kim G. Smolderen, PhD, Paul S. Chan, MD, MS and John Ryan, MD

Does a patient’s insurance status affect a physician’s decision to prescribe evidence-based therapies for CAD?

---

January 28th, 2013

Getting a Read on St. Jude Leads: An Interview with Robert G. Hauser

Robert George Hauser, BS MD and John Ryan, MD

The researcher and EP who first documented problems with St. Jude next generation leads reacts to the FDA’s recent letter to the company and explains what he is doing for patients who have received these devices.

---

January 22nd, 2013

Renal Denervation: Delineating Its Uses, Misuses, and Possibilities

Murray David Esler, MBBS PhD and John Ryan, MD

Is Renal Denervation a cure? A likely overused “magic bullet” in patients who should receive more behavior modification and drug treatment? Where exactly should it fit in our arsenal? John Ryan interviews Murray David Esler

---

January 17th, 2013

Revisiting Novel Anticoagulants in Atrial Fibrillation

John Ryan, MD and Christian Thomas Ruff, MD, MPH

Two experts discuss the evolving landscape of novel anticoagulants for patients with AF. Do you agree with their perspectives? What questions do you have? What has your experience taught you?

---

January 10th, 2013

A New Dimension in Serial LVEF Measurement

Thomas Marwick and John Ryan, MD

John Ryan asks Thomas Marwick about his new study, which found that the most reproducible technique for serial assessment of LVEF is the noncontrast 3D echocardiogram.

---

January 4th, 2013

Why Has Niacin Therapy Failed to THRIVE?

William Edward Boden, MD and John Ryan, MD

In the wake of HPS2-THRIVE, John Ryan asks William E. Boden, lead investigator of the AIM-HIGH trial, for his perspective on niacin and other HDL-modifying therapies.

---

December 12th, 2012

AMPLIFYING Treatment for DVT/PE

John Ryan, MD

John Ryan reviews the latest data and suggests that DVT/PE be managed as a chronic condition. Are you using apixaban in these patients, and how long are you treating them for?

---

November 28th, 2012

The End of Fellowship: What Happens Next?

John Ryan, MD

Our training programs have a uniform deficiency — they do not prepare fellows on how to leave. I know this well, as I am currently transitioning from cardiology fellow to faculty member. Fellows typically enter medical school in their twenties and over the next ten years become institutionalized into full-time understudies. Part of this is nice, […]

---

October 22nd, 2012

The Highs and Lows of Fellowship Interviews

John Ryan, MD

Fellow John Ryan shares the story of an interview that goes awry; what has your experience been?

---

October 8th, 2012

Triple Antithrombotic Therapy: What — and When — Is the Bleeding Risk?

Morten Lamberts, MD and John Ryan, MD

Morten Lamberts, MD, lead investigator of a recent registry study of various combinations of antithrombotic agents in patients with AF and CAD, answers John Ryan’s questions about the study and its implications.

---